Viviana García-Horton
New York
Education
Ph.D. and A.M., statistics, Harvard University; B.S., applied mathematics, Autonomous Technological Institute of Mexico
Summary of Experience
Dr. García-Horton is a statistician who specializes in the application of advanced statistical techniques to the field of health economics and outcomes research (HEOR). She has broad experience developing research and strategies in a wide range of disease areas, including diabetes, oncology, hematology, rare diseases, dermatology, psychiatry, neurology, and gastroenterology. Dr. García-Horton’s expertise includes causal inference for experimental and observational data, predictive modeling, missing data problems, Bayesian statistics, clinical trial design and analysis, indirect treatment comparisons, individualized medicine, and retrospective claims database analyses. Her work includes developing network meta-analyses for regulatory submission, treatment patterns and economic outcomes research using retrospective claims analyses, clinical trial data analyses, and analyses of patient-reported outcomes (PROs) to support approved product labeling. Dr. García-Horton’s research has been published in peer-reviewed journals and presented at numerous clinical research, health economics, and statistics conferences.
Selected Publishing
-
Matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma
Cancer Medicine, 2023
2023Richter J, Lin PL, Garcia-Horton V, Guyot P, Singh E, Zhou ZY, Sievert M, Taiji R
-
Economic Impact of Recurrent Clostridioides difficile Infection in the USA: A Systematic Literature Review and Cost Synthesis
Advances in Therapy, 2023
2023Reveles KR, Yang M, Garcia-Horton V, Edwards ML, Guo A, Lodise T, Bochan M, Tillotson G, Dubberke ER
-
Safety Differences across Androgen Receptor Inhibitors in Nonmetastatic Castration-Resistant Prostate Cancer
Future Oncology, 2023
2023Shore N, Garcia-Horton V, Terasawa E, Ayyagari R, Grossman JP, Waldeck AR
-
Adalimumab Is Associated With Lower Healthcare Resource and Steroid Use Versus Vedolizumab in Biologic-Naive Crohn's Disease: A Retrospective Claims Database Analysis
Crohn's & Colitis 360, 2022
2022Ungaro RC, Griffith J, Garcia-Horton V, Wang A, Cross RK
-
The Hospitalization-Related Costs of Adverse Events for Novel Androgen Receptor Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: An Indirect Comparison
Advances in Therapy, 2022
2022Shore N, Jiang S, Garcia-Horton V, Terasawa E, Steffen D, Chin A, Ayyagari R, Partridge J, Waldeck AR
-
Patterns of Daily Motor-Symptom Control with Carbidopa/Levodopa Enteral Suspension Versus Oral Carbidopa/Levodopa Therapy in Advanced Parkinson’s Disease: Clinical Trial Post Hoc Analyses
Neurology and Therapy, 2022
2022Pahwa R, Aldred J, Gupta N, Terasawa E, Garcia-Horton V, Steffen DR, Kandukuri PL, Chaudhari VS, Jalundhwala YJ, Bao Y, Kukreja P, Isaacson SH
-
Real-World Adherence to Tetrabenazine or Deutetrabenazine Among Patients With Huntington's Disease: A Retrospective Database Analysis
Neurology and Therapy, 2022
2022Claassen DO, Ayyagari R, Garcia-Horton V, Zhang S, Alexander J, Leo S
-
Long-Term Results of Carbidopa/Levodopa Enteral Suspension across the Day in Advanced Parkinson’s Disease: Post-Hoc Analyses from a Large 54-Week Trial
Clinical Parkinsonism & Related Disorders, 2022
2022Pahwa R, Aldred J, Merola A, Gupta N, Terasawa E, Garcia-Horton V, Steffen DR, Kandukuri PL, Bao Y, Ladhani O, Yan CO, Chaudhari V, Isaacson SH
-
Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
The Journal of Urology, 2021
2021Halabi S, Jiang S, Terasawa E, García-Horton V, Ayyagari R, Waldeck AR, Shore N
-
Indirect Comparison of Darolutamide Versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
Journal of Urology, 2021
2021Halabi S, Jiang S, Terasawa E, Garcia-Horton V, Ayyagari R, Waldeck AR, Shore N
-
Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials
JAMA Dermatology, 2020
2020Augustin M, Lambert J, Zema C, Thompson EHZ, Yang M, Wu EQ, Garcia-Horton V, Geng Z, Valdes JM, Joshi A, Gordon KB
-
Patient and Oncologist Preferences for the Treatment of Adults with Advanced Soft Tissue Sarcoma: A Discrete Choice Experiment
The Patient: Patient-Centered Outcomes Research. January 19, 2019
2019Ivanova J, Hess LM, García-Horton V, Graham S, Liu X, Zhu Y, Nicol S
-
Comparative Efficacy of Treatments for Previously Treated Advanced or Metastatic Non-Small-Cell Lung Cancer: A Network Meta-Analysis
Advances in Therapy. 2018 Jul;35(7):1035-1048
2018Li J, Sasane M, Zhao J, García-Horton V, Zhang P, Ricculli ML, Zhou ZY, Signorovitch J
-
Characteristics, Treatment Patterns, and Economic Outcomes of Patients Initiating Injectable Medications for Management of Type 2 Diabetes Mellitus in Japan
Diabetes Therapy. 2018 Jun;9(3):1125-1141
2018Suzuki S, Desai U, Strizek A, Ivanova J, García-Horton V, Cai Z, Schmerold L, Liu X, Perez-Nieves M
News
-
June 27, 2023
-
March 2, 2023
-
December 10, 2021
-
April 13, 2021
-
January 12, 2021